Hepatitis C Community
telaprevir
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

telaprevir

Hi everyone,
I am reading up on telaprevir but found that so far there are only tests done with treatment naive patients (in France?!) I have been reading that for non-responders or relapsers this will only be an option in 3 to 5 years- on the other hand I hear from some of you that this is not the case for some of you - who can give me some info???
thanks in advance Béatrice
Related Discussions
6 Comments Post a Comment
Blank
220090_tn?1379170787
Vertex has an ongoing trial for non--responders and relapsers.  They refer to is as Prove 3.  It is a phase 2 trial in FDA terminology.  

Vertex is about to start a phase 3 trial (confusing since they called the phase 2 trial Prove 3) and I believe, but I am not sure, that it will include relapsers and non responders.  There are rumors that Vertex will apply for approval of the drug based on the success of the Prove 3 trial.  These are not substantiated, so it is anyones guess about when the drug will be available to the general public.  Some people talk about 2010 - 2011 time frame.
Blank
471014_tn?1207435481
thank you for this information
Blank
201379_tn?1319994931
The trial current listed on the clinical trials website is treatment naive only.  The trial for non-responders and relapsers comes later, but may be entirely done in Europe.  Keep your ears open and your eyes peeled.

"mom"
Blank
471014_tn?1207435481
Hi "mom",
where did you get this info? can you send me the link please?
(as I am in Europe!)
best greeting Béatrice
Blank
104550_tn?1237917191
You can go to there web site @ vertex.com

- First hepatitis C protease inhibitor to begin Phase 3 clinical development - - Trial designed to confirm potential of telaprevir to increase sustained viral response (SVR) rates with 24-week treatment duration -

CAMBRIDGE, Mass., Mar 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Tibotec today announced that patient screening has begun in the ADVANCE study, a pivotal Phase 3 clinical study with the hepatitis C virus (HCV) protease inhibitor telaprevir in combination therapy for treatment-naive patients with chronic HCV infection. Telaprevir is the most advanced HCV protease inhibitor in clinical development targeting treatment of hepatitis C, a disease that afflicts more than 3 million people in the United States alone, and 170 million worldwide. The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients and will evaluate two 24-week telaprevir-based regimens in comparison to a 48-week control arm. The primary endpoint of the study is sustained viral response (SVR), defined as undetectable HCV RNA (<10 IU/mL) 24 weeks after the completion of treatment. In this study, rapid viral response (RVR) criteria will be used to determine which telaprevir patients can stop all treatment at 24 weeks.

"This is the first Phase 3 study conducted to evaluate whether an investigational medicine for HCV may be able to both increase the rate of sustained viral response and shorten the duration of therapy to 24 weeks in patients with genotype 1 HCV infection compared to current treatment of 48 weeks. This is important given the expectation that approximately 40 to 50 percent of people with genotype 1 HCV who undergo treatment with current therapies achieve SVR," said John McHutchison, M.D., Associate Director, Duke Clinical Research Institute and a principal investigator for the ADVANCE study. "We're interested to see whether this trial will confirm the encouraging results seen thus far in Phase 2 studies of telaprevir. This study is another important step forward in the evaluation of novel medicines for the treatment of HCV."

"Following discussions with the U.S. FDA in January, we have been able to rapidly finalize the Phase 3 pivotal trial protocol and begin patient screening at the first sites," said John Alam, M.D., Executive Vice President, Medicines Development and Chief Medical Officer of Vertex. "The initiation of the ADVANCE trial underscores our commitment to evaluating the potential for telaprevir to address significant unmet medical needs in HCV."

The ADVANCE Study

The ADVANCE study (A New Direction in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with telaprevir) will be conducted at more than 100 centers in the U.S., E.U. and certain other countries. Patient recruitment is being initiated in the U.S., while sites in other countries will start recruitment as national Clinical Trial Applications (CTAs) for each country are approved. The study arms will include:

Blank
104550_tn?1237917191
Correction = vrtx.com to get to vertex web site
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating Control: How to St...
Aug 28 by Roger Gould, M.D.Blank
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
Top Hepatitis Answerers
446474_tn?1404424777
Blank
HectorSF
CA
317787_tn?1373214989
Blank
Dee1956
DC
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
Avatar_m_tn
Blank
can-do-man
IN
Avatar_f_tn
Blank
susan400
FL
766573_tn?1365170066
Blank
Idyllic